Thermo Fisher Scientific, Inc. has signed a definitive agreement to acquire Phadia, a global allergy and autoimmunity diagnostics firm, from European private equity firm Cinven, for approximately $3.5 billion in cash. The transaction is expected to be completed in 4Q11. Based in Uppsala, Sweden, Phadia develops, manufactures and markets complete blood-test systems to support the clinical diagnosis and monitoring of allergy and autoimmune diseases. Phadia operates through two leading brands: ...